Qihua Pan

Dong Xu, Jiantao Wu, Qihua Pan et al.

Drug-drug interaction (DDI) prediction is central to drug discovery and clinical development, particularly in the context of increasingly prevalent polypharmacy. Although existing computational methods achieve strong performance on standard benchmarks, they often fail to generalize to realistic deployment scenarios, where most candidate drug pairs involve previously unseen drugs and validated interactions are scarce. We demonstrate that proximity in the embedding spaces of prevailing molecule-centric DDI models does not reliably correspond to interaction labels, and that simply scaling up model capacity therefore fails to improve generalization. To address these limitations, we propose GenRel-DDI, a generalizable relation learning framework that reformulates DDI prediction as a relation-centric learning problem, in which interaction representations are learned independently of drug identities. This relation-level abstraction enables the capture of transferable interaction patterns that generalize to unseen drugs and novel drug pairs. Extensive experiments across multiple benchmark demonstrate that GenRel-DDI consistently and significantly outperforms state-of-the-art methods, with particularly large gains on strict entity-disjoint evaluations, highlighting the effectiveness and practical utility of relation learning for robust DDI prediction. The code is available at https://github.com/SZU-ADDG/GenRel-DDI.

Dong Xu, Qihua Pan, Sisi Yuan et al.

Molecular generative models, often employing GPT-style language modeling on molecular string representations, have shown promising capabilities when scaled to large datasets and model sizes. However, it remains unclear and subject to debate whether these models adhere to predictable scaling laws under fixed computational budgets, which is a crucial understanding for optimally allocating resources between model size, data volume, and molecular representation. In this study, we systematically investigate the scaling behavior of molecular language models across both pretraining and downstream tasks. We train 300 models and conduct over 10,000 experiments, rigorously controlling compute budgets while independently varying model size, number of training tokens, and molecular representation. Our results demonstrate clear scaling laws in molecular models for both pretraining and downstream transfer, reveal the substantial impact of molecular representation on performance, and explain previously observed inconsistencies in scaling behavior for molecular generation. Additionally, we publicly release the largest library of molecular language models to date to facilitate future research and development. Code and models are available at https://github.com/SZU-ADDG/MLM-Scaling.

Qihua Pan, Dong Xu, Jenna Xinyi Yao et al.

Powerful AI tools for drug discovery reside in isolated web apps, desktop programs, and code libraries. Such fragmentation forces scientists to manage incompatible interfaces and specialized scripts, which can be a cumbersome and repetitive process. To address this issue, a Full-pROcess druG dEsign ageNT, named FROGENT, has been proposed. Specifically, FROGENT utilizes a Large Language Model and the Model Context Protocol to integrate multiple dynamic biochemical databases, extensible tool libraries, and task-specific AI models. This agentic framework allows FROGENT to execute complicated drug discovery workflows dynamically, including component tasks such as target identification, molecule generation and retrosynthetic planning. FROGENT has been evaluated on eight benchmarks that cover various aspects of drug discovery, such as knowledge retrieval, property prediction, virtual screening, mechanistic analysis, molecular design, and synthesis. It was compared against six increasingly advanced ReAct-style agents that support code execution and literature searches. Empirical results demonstrated that FROGENT triples the best baseline performance in hit-finding and doubles it in interaction profiling, significantly outperforming both the open-source model Qwen3-32B and the commercial model GPT-4o. In addition, real-world cases have been utilized to validate the practicability and generalization of FROGENT. This development suggests that streamlining the agentic drug discovery pipeline can significantly enhance researcher productivity.